Abbott Receives FDA Approval for TriClip™, First-of-its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip™ transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve. This approval follows ...

Related Keywords

Canada ,Amplatzer Piccolo ,Dhaval Elmariah ,Sandra Lesenfants ,Lynnc Headrick ,Amplatzer Piccolo Occluder ,Paul Sorajja ,Facebook ,Youtube ,Drug Administration ,Minneapolis Heart Institute Foundation ,Instagram ,Linkedin ,Valve Science Center ,Circulatory System Devices Panel ,Medical Devices Advisory Committee ,Multichannel News Release ,Family Chair ,Structural Heart Disease ,Minneapolis Heart Institute ,Abbott Northwestern Hospital ,